Mvasi (Bevacizumab)

Bevacizumab binds selectively to vascular endothelial growth factor‑A (VEGF‑A), preventing it from activating VEGF receptors on endothelial cells. This inhibition blocks the formation of new blood vessels (angiogenesis) that tumours need for growth and metastasis, thereby slowing disease progression.

The dose of Mvasi is individualized by the treating physician based on the specific cancer type, patient weight or body surface area, and the therapeutic regimen. The prescriber determines the infusion volume, rate, and frequency according to approved guidelines.

Safety of bevacizumab in pregnancy has not been established and animal studies suggest potential fetal harm. It is generally contraindicated in pregnant women and should be avoided during breastfeeding because it may be excreted in milk. Consultation with a specialist is essential.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Mvasi. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and required import documentation.

Mvasi (bevacizumab) is a full‑length humanized IgG1 monoclonal antibody that directly neutralises VEGF‑A, whereas other agents such as ramucirumab target the VEGF receptor, and small‑molecule tyrosine‑kinase inhibitors block downstream signalling. Clinical choice depends on tumour type, prior therapy, safety profile and regulatory approval.

Mvasi must be stored refrigerated at 2 °C to 8 °C, protected from light, and must not be frozen or shaken. The product should be kept in its original packaging until use and inspected for particulate matter before preparation. Once prepared for infusion, it should be used within the time frame recommended by the manufacturer.

Mvasi is supplied as an intravenous solution that is administered by a qualified healthcare professional. The infusion is given through a peripheral or central venous line over a period typically ranging from 30 minutes to 90 minutes, depending on the dose and patient tolerance. Infusion rates may be adjusted if reactions occur.

The most serious adverse events linked to bevacizumab include severe hypertension, arterial thromboembolic events, gastrointestinal perforation, severe bleeding, wound‑healing complications, and rare cases of posterior reversible encephalopathy syndrome. Patients should be monitored closely for these conditions, and treatment should be discontinued if any life‑threatening event occurs.

Mvasi is contraindicated in patients with known hypersensitivity to bevacizumab or any component of the formulation, in those with uncontrolled hypertension, recent major surgery or non‑healing wounds, and in pregnant women. Caution is also advised for individuals with a history of arterial thromboembolism, gastrointestinal perforation, or severe bleeding disorders.